Maternal family history is associated with Alzheimer's disease biomarkers

Journal of Alzheimer's Disease

Volumn 31, Issue 3, 2012, Pages 659-668

  Honea, Robyn A ^a   Vidoni, Eric D ^a   Swerdlow, Russell H ^a   Burns, Jeffrey M ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; cerebrospinal fluid; genetics; PET

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMENTIA; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PARIETAL CORTEX; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PRIORITY JOURNAL; REVIEW; SENSORIMOTOR CORTEX; SEX ROLE;

EID: 84865581809     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120676     Document Type: Review

References (37)

1. Farrer LA, O'Sullivan DM, Cupples LA, Growdon JH, Myers RH (1989) Assessment of genetic risk for Alzheimer's disease among first-degree relatives. Ann Neurol 25, 485-493. (Pubitemid 19136680)
2. Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green RC (2004) Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: The REVEAL study. Genet Med 6, 192-196. (Pubitemid 39005858)
3. Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, Farrer LA (2002) Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 287, 329-336. (Pubitemid 34251966)
4. Honea RA, Swerdlow RH, Vidoni ED, Burns JM (2011) Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology 76, 822-829.
5. Honea RA, Swerdlow RH, Vidoni ED, Goodwin J, Burns JM (2010) Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 74, 113-120.
6. Mosconi L, Brys M, Switalski R, Mistur R, Glodzik L, Pirraglia E, Tsui W, De Santi S, de Leon MJ (2007) Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA 104, 19067-19072.
7. Mosconi L, Mistur R, Switalski R, Brys M, Glodzik L, Rich K, Pirraglia E, Tsui W, De Santi S, de Leon MJ (2009) Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 72, 513-520.
8. Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, Murray J, Scheinin N, Nagren K, Williams S, Glodzik L, De Santi S, Vallabhajosula S, de Leon MJ (2010) Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci USA 107, 5949-5954.
9. Mosconi L, Glodzik L, Mistur R, McHugh P, Rich KE, Javier E, Williams S, Pirraglia E, De Santi S, Mehta PD, Zinkowski R, Blennow K, Pratico D, de Leon MJ (2010) Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biol Psychiatry 68, 913-921.
10. Mosconi L, Berti V, Swerdlow RH, Pupi A, Duara R, de Leon M (2010) Maternal transmission of Alzheimer's disease: Prodromal metabolic phenotype and the search for genes. Hum Genomics 4, 170-193.
11. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412b-2414.
12. Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA (2007) The National Alzheimer's Coordinating Center (NACC) database: The Uniform Data Set. Alzheimer Dis Assoc Disord 21, 249-258. (Pubitemid 47367978)
13. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental State: A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 12, 189-198.
14. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
15. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
16. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121, 597-609.
17. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365.
18. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM Mintun MA APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67, 122-131.
19. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ (2011) Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 76, 69-79.
20. Xiong CJ, Roe CM, Buckles V, Fagan A, Holtzman D, Balota D, Duchek J, Storandt M, Mintun M, Grant E, Snyder AZ, Head D, Benzinger TLS, Mettenburg J, Csernansky J, Morris JC (2011) Role of family history for Alzheimer biomarker abnormalities in the adult children study. Arch Neurol 68, 1311-1317.
21. Ewers M, Insel P, Jagust WJ, Shaw L, Trojanowski JJ, Aisen P, Petersen RC, Schuff N, Weiner MW (2011) CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex, doi: 10.1093/cercor/bhr271.
22. Bai F, Zhang Z, Yu H, Shi Y, Yuan Y, Zhu W, Zhang X, Qian Y (2008) Default-mode network activity distinguishes amnestic type mild cognitive impairment from healthy aging: Acombined structural and resting-state functional MRI study. Neurosci Lett 438, 111-115.
23. Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, Beckmann CF, Mackay CE (2009) Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci USA 106, 7209-7214.
24. Honea RA, Swerdlow RH, Vidoni ED, Burns JM (2010) Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology 76, 822-829.
25. Ikonomovic MD, Klunk WE, Abrahamson EE, Wuu J, Mathis CA, Scheff SW, Mufson EJ, DeKosky ST (2011) Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology 77, 39-47.
26. Andrawis JP, Hwang KS, Green AE, Kotlerman J, Elashoff D, Morra JH, Cummings JL, Toga AW, Thompson PM, Apostolova LG (2010) Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging 33, 856-866.
27. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
28. Buerger K, Ewers M, Andreasen N, Zinkowski R, Ishiguro K, Vanmechelen E, Teipel SJ, Graz C, Blennow K, Hampel H (2005) Phosphorylated tau predicts rate of cognitive decline in MCI subjects: A comparative CSF study. Neurology 65, 1502-1503. (Pubitemid 41552795)
29. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234. (Pubitemid 43238346)
30. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K (2007) Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 78, 461-464. (Pubitemid 46662891)
31. Bonilla E, Tanji K, Hirano M, Vu TH, DiMauro S, Schon EA (1999) Mitochondrial involvement in Alzheimer's disease. Biochim Biophys Acta 1410, 171-182. (Pubitemid 29078603)
32. Orth M, Schapira AH (2001) Mitochondria and degenerative disorders. Am J Med Genet 106, 27-36. (Pubitemid 32601615)
33. Cardoso SM, Santana I, Swerdlow RH, Oliveira CR (2004) Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 89, 1417-1426. (Pubitemid 38802663)
34. Parker WD Jr, Filley CM, Parks JK (1990) Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40, 1302-1303. (Pubitemid 20244999)
35. Swerdlow RH (2007) Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J Neurosci Res 85, 3416-3428. (Pubitemid 350058530)
36. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP Jr, Davis RE, Parker WD Jr (1997) Cybrids in Alzheimer's disease: A cellular model of the disease? Neurology 49, 918-925. (Pubitemid 27456066)
37. Mosconi L, de Leon M, Murray EL, Lu J, Javier E, McHugh P, Swerdlow RH (2011) Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease. J Alzheimers Dis 27, 483-490.